Iovance Biotherapeutics (IOVA) price targets raised following FDA accelerated approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St futures gain as AI enthusiasm eases worries over higher oil prices, yields
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil slides as US-Iran truce hopes outweigh Houthi attacks on Saudi Arabia
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Iovanace Biotherapeutics (IOVA) PT Raised to $18 at Piper Sandler
February 20, 2024 7:31 AM ESTPiper Sandler analyst Joseph Catanzaro raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $18.00 (from $14.00) while maintaining a Overweight rating.... More
Iovanace Biotherapeutics (IOVA) PT Raised to $22 at Wells Fargo
February 20, 2024 7:11 AM ESTWells Fargo analyst Nick Abbott raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $22.00 (from $17.00) while maintaining a Overweight rating.... More
Iovanace Biotherapeutics (IOVA) PT Raised to $32 at H.C. Wainwright
February 20, 2024 6:40 AM ESTH.C. Wainwright analyst Joseph Pantginis raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $32.00 (from $28.00) while maintaining a Buy rating.... More
Iovance Biotherapeutics (IOVA) Prices 23M Share Offering at $9.15/sh
February 20, 2024 6:30 AM ESTIovance Biotherapeutics, Inc. (Nasdaq: IOVA) today announced the pricing of an underwritten offering of 23,014,000 shares of its common stock at an offering price of $9.15 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be approximately $211 million. The offering is expected to close on or about February 22, 2024, subject to customary closing conditions.
Iovance intends to use the proceeds from... More
Iovanace Biotherapeutics (IOVA) PT Raised to $26 at Baird
February 20, 2024 6:24 AM ESTBaird analyst Colleen Kusy raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $26.00 (from $20.00) while maintaining a Outperform rating.... More
Iovanace Biotherapeutics (IOVA) PT Raised to $19 at Goldman Sachs
February 20, 2024 4:56 AM ESTGoldman Sachs analyst Andrea Tan raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $19.00 (from $13.00) while maintaining a Buy rating.... More
